An assistant professor from the University of Nevada, Las Vegas, whose work focuses on the molecular mechanisms underlying amyotrophic lateral sclerosis (ALS), has been named the first recipient of the MDA Research Momentum Award, a new honor from the Muscular Dystrophy Association (MDA) for early-career scientists. According to an MDA…
Early-career ALS scientist wins first MDA Research Momentum Award
Early treatment with PrimeC, an experimental oral treatment being developed by Neurosense Therapeutics, significantly extended survival in people with amyotrophic lateral sclerosis (ALS) by more than 14 months compared with a six-month delay in treatment initiation. That’s according to additional long-term data from PARADIGM (NCT05357950), a completed…
The amyotrophic lateral sclerosis (ALS) community is mourning the loss of Eric Dane, the “Grey’s Anatomy” star who turned his personal battle with the disease into a crusade for a cure. Dane died Thursday at the age of 53, one year after a diagnosis that saw him trade his…
A Look Behind the Care: Inside One Care Partner’s ALS Story
This content is sponsored by Tanabe Pharma America, Inc. (TPA) and is intended for US audiences only. Any other present or future content posted by the contributor, not expressly designated as “Tanabe Pharma America, Inc. – sponsored content” is not associated with TPA. The information provided here is general in…
A U.S. biotech company’s experimental oral therapy, neflamapimod, designed to treat age-related brain disorders, has been selected for inclusion in the EXPERTS-ALS platform study, a U.K. initiative aiming to rapidly test potential treatments for amyotrophic lateral sclerosis (ALS). Developer Cervomed announced in a company press release that its treatment…
A triple combination therapy has shown promise for treating sporadic amyotrophic lateral sclerosis (ALS), according to a new study that used cell models of the disease to screen more than 100 therapeutic compounds. The new cell-based model was created from motor neurons, or nerve cells, derived from people with…
My husband, Todd, finally got in his new wheelchair! After it was delivered in September, I wrote that we needed to have the attendant control reprogrammed. That finally happened, and we’ve been fine-tuning the chair over the past week. Although both are the same brand, there are differences between…
For most people, February is a month filled with hearts and flowers. But for me, it’s all that plus a vibrant display of ALS zebras and a splash of green, pink, blue, and purple. Zebras? You might wonder what a striped animal has to do with a neurological disease…
The ALS Society of Canada (ALS Canada) and Brain Canada have awarded a combined $515,000 to support four early-career clinicians and researchers advancing care and scientific understanding of amyotrophic lateral sclerosis (ALS). ALS Canada and Brain Canada have been partners since 2014, with early support stemming from…
The U.S.-based advocacy group I AM ALS has secured $313 million in new federal funding for Push for Progress, an effort the nonprofit launched in late 2025 to accelerate research and expand access to treatments for amyotrophic lateral sclerosis (ALS). In a press release announcing the…
Recent Posts
- After 15 years as an ALS caregiver, I’m still learning from others
- Early PrimeC use slows ALS progression, reduces complication risk
- Learning ALS self-advocacy involves being a little pushy
- Brain implant decodes finger moves so paralyzed patients can type
- Grant funds new ALS treatment approach targeting TDP-43 pathway